Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics reports CD22 antibody produced significant anti-tumor response

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Children's Hospital LA investigators elected into the Society for Pediatric Research

Children's Hospital LA investigators elected into the Society for Pediatric Research

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

No overall cancer risk in people who donate stem cells

No overall cancer risk in people who donate stem cells

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Asuragen, Novartis to develop ARQ BCR-ABL1 RNA IS Calibrators, laboratory software reporting tools

Asuragen, Novartis to develop ARQ BCR-ABL1 RNA IS Calibrators, laboratory software reporting tools

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

New research focusing on VTE presented at ASH Annual Meeting

New research focusing on VTE presented at ASH Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.